Sensitization of (colon) cancer cells to death receptor related therapies: A report from the FP6-ONCODEATH research consortium

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 458-466

  Pintzas, Alexander ^a   Zhivotovsky, Boris ^b   Workman, Paul ^c   Clarke, Paul A ^c   Linardopoulos, Spiros ^c   Martinou, Jean Claude ^d   Lacal, Juan Carlos ^e   Robine, Sylvie ^f   Nasioulas, George ^g   Andera, Ladislav ^h  

^a INSTITUTE OF BIOLOGY   (Greece)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^f INSTITUT CURIE   (France)

^g GeneKor SA   (Greece)

^h INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Cancer; Death receptors; Kinase inhibitors; Mitochondria; Oncogenes; Rational combinations; Targeted therapies

Indexed keywords

AURORA KINASE INHIBITOR; B RAF KINASE; CHOLINE KINASE; DEATH RECEPTOR; DNA METHYLTRANSFERASE INHIBITOR; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; CANCER CELL; COLON CANCER; CONCENTRATION RESPONSE; EXPRESSION VECTOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; NONHUMAN; ONCOGENE; PHARMACOGENOMICS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION;

EID: 84861121305     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19600     Document Type: Review

References (60)

1. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005; 94:143-96; PMID:16096001; http://dx.doi.org/10.1016/S0065-230X(05)94004-9.
2. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365:153-65; PMID:15639298; http://dx.doi.org/10. 1016/S0140- 6736(05)17706-X.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766.
4. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010; 16:3329-34; PMID:20472680; http://dx.doi.org/10.1158/1078-0432.CCR-09-3064.
5. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70:2146-57; PMID:20179189; http://dx.doi.org/10.1158/0008-5472.CAN-09-4355.
6. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18:64-76; PMID:22215907; http://dx.doi. org/10.1158/1078-0432.CCR-11-1000.
7. Hernando E, Sarmentero-Estrada J, Koppie T, Belda- Iniesta C, Ramírez de Molina V, Cejas P, et al. A critical role for choline kinasealpha in the aggressiveness of bladder carcinomas. Oncogene 2009; 28:2425- 35; PMID:19448670; http://dx.doi.org/10.1038/ onc.2009.91.
8. Ramírez de Molina A, Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005; 65:5647-53; PMID:15994937; http://dx.doi. org/10.1158/0008-5472.CAN-04-4416.
9. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010; 70:4655-65; PMID:20460511; http://dx.doi. org/10.1158/0008-5472.CAN-09-3953.
10. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-8; PMID:9721089; http://dx.doi.org/10.1126/science. 281.5381.1305.
11. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118:100-10; PMID:18079967; http://dx.doi. org/10.1172/JCI33061.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63; PMID:9930862; http://dx.doi. org/10.1038/5517.
13. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27:6207- 15; PMID:18931688; http://dx.doi.org/10.1038/ onc.2008.298.
14. Wu XX, Kakehi Y. Enhancement of lexatumumabinduced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 2009; 15:2039-47; PMID:19276256; http:// dx.doi.org/10.1158/1078-0432.CCR-08- 2667.
15. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007; 13:3403-12; PMID:17545549; http://dx.doi. org/10.1158/1078- 0432.CCR-07-0251.
16. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, et al. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 2007; 97:73-84; PMID:17551494; http://dx.doi.org/10.1038/sj.bjc.6603835.
17. Drosopoulos K, Pintzas A. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert Opin Ther Targets 2007; 11:641-59; PMID:17465723; http://dx.doi. org/10.1517/14728222.11.5.641.
18. Grandemange S, Herzig S, Martinou JC. Mitochondrial dynamics and cancer. Semin Cancer Biol 2009; 19:50- 6; PMID:19138741; http://dx.doi.org/10.1016/j. sem-cancer. 2008.12.001.
19. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11:431-49; PMID:21263219; http://dx.doi. org/10.4161/cbt.11.5.14671.
20. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5:501-12; PMID:15144957; http://dx.doi. org/10.1016/S1535-6108(04) 00113-8.
21. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factoralpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004; 64:3922-7; PMID:15173003; http://dx.doi.org/10.1158/0008-5472.CAN-03-2219.
22. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by upregulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005; 280:22856-67; PMID:15757891; http://dx.doi.org/10.1074/jbc.M412483200.
23. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131:1096-109; PMID:17030180; http://dx.doi. org/10.1053/j.gastro.2006.08.011.
24. Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del Pulgar MT, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007; 170:1077-85; PMID:17322390; http://dx.doi.org/10.2353/ ajpath.2007.060773.
25. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, et al. The phosphoinositide- 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010; 70:5507-17; PMID:20551061; http://dx.doi.org/10.1158/0008-5472.CAN-09-4476.
26. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis and metastasis. Cancer Res 2008; 68:2850-60; PMID:18413753; http://dx.doi. org/10.1158/0008-5472.CAN-07-5256.
27. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, et al. Acquired resistance to 17-allylamino- 17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009; 69:1966-75; PMID:19244114; http://dx.doi.org/10.1158/0008-5472.CAN-08-3131.
28. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010; 9:1219-33; PMID:20457619; http://dx.doi.org/10.1158/1535-7163.MCT-09-0683.
29. Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007; 6:3147-57; PMID:18089709; http://dx.doi. org/10.1158/1535-7163.MCT-07-2156.
30. Psahoulia FH, Moumtzi S, Roberts ML, Sasazuki T, Shirasawa S, Pintzas A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 2007; 28:1021-31; PMID:17148506; http://dx.doi.org/10.1093/carcin/bgl232.
31. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6:2591-9; PMID:17876056; http://dx.doi.org/10.1158/1535-7163.MCT-07-0001.
32. V600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011; 6:21632; PMID:21738740; http://dx.doi.org/10.1371/journal.pone.0021632.
33. Rodríguez-González A, Ramírez de Molina A, Fernández F, Ramos MA, del Carmen Núñez M, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003; 22:8803-12; PMID:14654777; http://dx.doi.org/10.1038/sj.onc.1207062.
34. Rodríguez-González A, Ramírez de Molina A, Fernández F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23:8247-59; PMID:15378008; http://dx.doi. org/10.1038/sj.onc.1208045.
35. Bañez-Coronel M, Ramírez de Molina A, Rodríguez- González A, Sarmentero J, Ramos MA, García-Cabezas MA, et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008; 8:709-19; PMID:19075594; http://dx.doi. org/10.2174/ 156800908786733432.
36. Quintás-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9:1029-37; PMID:18377344; http://dx.doi. org/10.1517/14656566.9.6.1029.
37. Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 2010; 9:87; PMID:20416058; http://dx.doi.org/10. 1186/1476-4598-9-87.
38. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32:1450-8; PMID:21771726; http://dx.doi. org/10.1093/carcin/bgr135.
39. Símová S, Klíma M, Cermak L, Sourková V, Andera L. Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. Apoptosis 2008; 13:423-36; PMID:18165900; http://dx.doi.org/10.1007/s10495- 007-0171-8.
40. Oikonomou E, Kosmidou V, Katseli A, Kothonidis K, Mourtzoukou D, Kontogeorgos G, et al. TRAIL Receptor Upregulation Correlates to KRAS/BRAF Mutations in Human Colon Cancer Tumors and Respective Normal Tissue. Int J Cancer 2009; 125:2127-35; PMID:19637313; http://dx.doi. org/10.1002/ijc.24613.
41. Ramírez de Molina A, Sarmentero-Estrada J, Belda- Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007; 8:889-97; PMID:17851129; http://dx.doi.org/10.1016/S1470- 2045(07)70279-6.
42. Sayan AE, Sayan BS, Gogvadze V, Dinsdale D, Nyman U, Hansen TM, et al. p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 2008; 27:4363- 72; PMID:18362891; http://dx.doi.org/10.1038/ onc.2008.64.
43. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S. Aurora-A regulation of nuclear factorkappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007; 67:1689-95; PMID:17308110; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2272.
44. Lucken-Ardjomande S, Montessuit S, Martinou JC. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ 2008; 15:929-37; PMID:18259190; http://dx.doi.org/10.1038/cdd. 2008.9.
45. Lucken-Ardjomande S, Montessuit S, Martinou JC. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ 2008; 15:484- 93; PMID:18084240; http://dx.doi.org/10.1038/ sj.cdd.4402280.
46. Montessuit S, Somasekharan SP, Terrones O, Lucken- Ardjomande S, Herzig S, Schwarzenbacher R, et al. Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell 2010; 142:889-901; PMID:20850011; http://dx.doi. org/10.1016/j.cell.2010.08.017.
47. Olsson M, Vakifahmetoglu H, Abruzzo PM, Högstrand K, Grandien A, Zhivotovsky B. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. Oncogene 2009; 28:1949-59; PMID:19347032; http://dx.doi.org/10.1038/ onc.2009.36.
48. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14:250-62; PMID:18772114; http://dx.doi. org/10.1016/j.ccr.2008.08.002.
49. Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM, et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell 2008; 31:886- 95; PMID:18922470; http://dx.doi.org/10.1016/j. molcel.2008.07.021.
50. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63; PMID:9930862; http://dx.doi. org/10.1038/5517.
51. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10. 1016/1074-7613(95)90057-8.
52. de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001; 20:51-6; PMID:11831647; http://dx.doi. org/10.1023/A:1013112624971.
53. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277:768; PMID:9273698; http:// dx.doi.org/10.1126/science.277.5327.768.
54. Voelkel-Johnson C, Hannun YA, El-Zawahry A. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring downregulation of cellular FLICE inhibitory protein. Mol Cancer Ther 2005; 4:1320-7; PMID:16170023; http://dx.doi. org/10.1158/1535-7163.MCT-05-0086.
55. White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 2009; 28:1132-41; PMID:19137010; http://dx.doi. org/10.1038/onc.2008.468.
56. Rodríguez-González A, Ramirez de Molina A, Fernández F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23:8247-59; PMID:15378008; http://dx.doi. org/10.1038/sj.onc.1208045.
57. Zhivotovsky B, Orrenius S. Clinical perspectives of cell death: where we are and where to go... Apoptosis 2009; 14:333-5; PMID:19238546; http://dx.doi. org/10.1007/s10495-009-0326-x.
58. Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 2010; 17:561- 77; PMID:20609406; http://dx.doi.org/10. 1016/j. chembiol.2010.05.013.
59. Workman P, de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr Opin Pharmacol 2008; 8:359-62; PMID:18678282; http://dx.doi. org/10.1016/j.coph.2008.07.007.
60. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10:514-23; PMID:20535131; http://dx.doi.org/10.1038/nrc2870.